vs
Side-by-side financial comparison of Armour Residential REIT, Inc. (ARR) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.
Armour Residential REIT, Inc. is the larger business by last-quarter revenue ($50.4M vs $38.3M, roughly 1.3× ImmunityBio, Inc.). Armour Residential REIT, Inc. runs the higher net margin — 420.2% vs -161.8%, a 582.0% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 297.9%).
Armour Residential REIT, Inc. is a U.S.-based real estate investment trust that primarily invests in agency residential mortgage-backed securities guaranteed by U.S. government-sponsored entities. It focuses on generating consistent long-term net income for shareholders via strategic asset management and active interest rate risk mitigation.
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
ARR vs IBRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $50.4M | $38.3M |
| Net Profit | $211.7M | $-61.9M |
| Gross Margin | — | 99.0% |
| Operating Margin | — | -169.0% |
| Net Margin | 420.2% | -161.8% |
| Revenue YoY | 297.9% | 407.0% |
| Net Profit YoY | 555.9% | -4.7% |
| EPS (diluted) | $2.43 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $50.4M | $38.3M | ||
| Q3 25 | $38.5M | $32.1M | ||
| Q2 25 | $33.1M | $26.4M | ||
| Q1 25 | $36.3M | $16.5M | ||
| Q4 24 | $12.7M | $7.6M | ||
| Q3 24 | — | $6.1M | ||
| Q2 24 | $7.0M | — | ||
| Q1 23 | $12.2M | — |
| Q4 25 | $211.7M | $-61.9M | ||
| Q3 25 | $159.3M | $-67.3M | ||
| Q2 25 | $-75.6M | $-92.6M | ||
| Q1 25 | $27.3M | $-129.6M | ||
| Q4 24 | $-46.4M | $-59.2M | ||
| Q3 24 | — | $-85.7M | ||
| Q2 24 | $-48.4M | — | ||
| Q1 23 | $-31.4M | — |
| Q4 25 | — | 99.0% | ||
| Q3 25 | — | 99.4% | ||
| Q2 25 | — | 99.5% | ||
| Q1 25 | — | 99.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — |
| Q4 25 | — | -169.0% | ||
| Q3 25 | — | -173.5% | ||
| Q2 25 | — | -269.8% | ||
| Q1 25 | — | -390.1% | ||
| Q4 24 | — | -919.0% | ||
| Q3 24 | — | -1314.3% | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — |
| Q4 25 | 420.2% | -161.8% | ||
| Q3 25 | 413.5% | -209.8% | ||
| Q2 25 | -228.4% | -350.3% | ||
| Q1 25 | 75.2% | -784.9% | ||
| Q4 24 | -366.8% | -783.4% | ||
| Q3 24 | — | -1404.0% | ||
| Q2 24 | -693.8% | — | ||
| Q1 23 | -256.8% | — |
| Q4 25 | $2.43 | $-0.06 | ||
| Q3 25 | $1.49 | $-0.07 | ||
| Q2 25 | $-0.94 | $-0.10 | ||
| Q1 25 | $0.32 | $-0.15 | ||
| Q4 24 | $-0.91 | $-0.08 | ||
| Q3 24 | — | $-0.14 | ||
| Q2 24 | $-1.05 | — | ||
| Q1 23 | $-0.95 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.3M | $242.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3B | $-500.5M |
| Total Assets | $21.0B | $501.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.3M | $242.8M | ||
| Q3 25 | $44.2M | $257.8M | ||
| Q2 25 | $141.2M | $153.7M | ||
| Q1 25 | $49.1M | $61.6M | ||
| Q4 24 | $68.0M | $149.8M | ||
| Q3 24 | — | $130.4M | ||
| Q2 24 | $126.6M | — | ||
| Q1 23 | — | — |
| Q4 25 | $2.3B | $-500.5M | ||
| Q3 25 | $2.1B | $-524.3M | ||
| Q2 25 | $1.7B | $-570.7M | ||
| Q1 25 | $1.7B | $-591.4M | ||
| Q4 24 | $1.4B | $-489.1M | ||
| Q3 24 | — | $-745.1M | ||
| Q2 24 | $1.2B | — | ||
| Q1 23 | $1.2B | — |
| Q4 25 | $21.0B | $501.9M | ||
| Q3 25 | $19.4B | $519.0M | ||
| Q2 25 | $16.2B | $402.1M | ||
| Q1 25 | $15.5B | $303.8M | ||
| Q4 24 | $13.5B | $382.9M | ||
| Q3 24 | — | $364.6M | ||
| Q2 24 | $10.1B | — | ||
| Q1 23 | $13.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $124.2M | $-70.4M |
| Free Cash FlowOCF − Capex | — | $-71.3M |
| FCF MarginFCF / Revenue | — | -186.2% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | 0.59× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-308.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $124.2M | $-70.4M | ||
| Q3 25 | $-37.8M | $-68.9M | ||
| Q2 25 | $25.0M | $-79.7M | ||
| Q1 25 | $101.5M | $-85.9M | ||
| Q4 24 | $261.5M | $-85.1M | ||
| Q3 24 | — | $-98.8M | ||
| Q2 24 | $27.1M | — | ||
| Q1 23 | $54.2M | — |
| Q4 25 | — | $-71.3M | ||
| Q3 25 | — | $-69.6M | ||
| Q2 25 | — | $-80.8M | ||
| Q1 25 | — | $-87.0M | ||
| Q4 24 | — | $-87.3M | ||
| Q3 24 | — | $-101.6M | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — |
| Q4 25 | — | -186.2% | ||
| Q3 25 | — | -217.2% | ||
| Q2 25 | — | -305.9% | ||
| Q1 25 | — | -526.9% | ||
| Q4 24 | — | -1155.4% | ||
| Q3 24 | — | -1663.2% | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — |
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 4.1% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | 28.0% | ||
| Q3 24 | — | 45.7% | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — |
| Q4 25 | 0.59× | — | ||
| Q3 25 | -0.24× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.71× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
